Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2023-10-04 Transaction in Own Shar…
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad informa de las operaciones de adquisición de acciones propias en el periodo transcurrido entre el 1 de septiembre y el 30 de septiembre de 2023.
Transaction in Own Shares Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (Spanish Securities Market Commission) dated October 4, 2023. The content explicitly details 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) regarding 'Adquisición de Acciones Propias' (Acquisition of Own Shares) conducted by Pharma Mar, S.A. during September 2023, providing detailed transaction tables. This type of filing, reporting the company's own share transactions (buybacks), directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a management report (MDA) or an earnings release (ER).
2023-10-04 Spanish
La Sociedad informa de las operaciones de adquisición de acciones propias en el periodo transcurrido entre el 1 de agosto y el 31 de agosto de 2023.
Transaction in Own Shares Classification · 100% confidence The document is a formal communication dated September 6, 2023, addressed to the Spanish National Securities Market Commission ("Comisión Nacional del Mercado de Valores"). The content explicitly details transactions related to the "Adquisición de Acciones Propias" (Acquisition of Own Shares) conducted by Pharma Mar, S.A. during August 2023. This type of filing, reporting the company's own share purchases, directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although it references a prior announcement, the core of this document is the detailed report of the transactions themselves, not just an announcement of a report's publication.
2023-09-06 Spanish
La Sociedad anuncia iniciar la adquisición de acciones propias al amparo de la autorización conferida por la Junta General de Accionistas y la suspensión temporal del vigente contrato de liquidez.
Transaction in Own Shares Classification · 100% confidence The document is a formal notification ('OTRA INFORMACIÓN RELEVANTE') addressed to the Spanish National Securities Market Commission ('Comisión Nacional del Mercado de Valores'). The core subject matter is the decision by Pharma Mar, S.A. to carry out the acquisition of its own shares ('Adquisición de Acciones Propias') based on prior shareholder authorization. This action involves setting limits on the number of shares (540,000) and the maximum monetary amount (€15,000,000.00) for the repurchase program, along with defining its duration (August 1, 2023, to January 31, 2024). This activity directly corresponds to the definition of a company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS).
2023-07-27 Spanish
La Sociedad anuncia que su socio Immedica Pharma AB ha recibido la aprobación completa para la comercialización de Zepzelca® (lurbinectedina) en Omán.
Regulatory Filings Classification · 100% confidence The document is a formal communication dated July 19, 2023, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - the Spanish securities market regulator). It is titled 'OTRA INFORMACIÓN RELEVANTE' (OTHER RELEVANT INFORMATION) and explicitly states that it is being provided in compliance with Spanish securities law (Ley 6/2023). The core content announces that PharmaMar's partner, Immedica, received marketing approval for Zepzelca® in Oman. Crucially, the document states, 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia' (A press release that will be distributed to the media regarding this news is attached). This structure—a brief regulatory filing forwarding an attached press release about a business development—is characteristic of an announcement intended for immediate public disclosure via regulatory channels, rather than the full report itself (like an ER or IR). Since it is a general regulatory announcement that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS (Regulatory Filings), or potentially an Earnings Release (ER) if the news was material to recent performance, but RNS is safer for general material news announcements not tied to a specific earnings period. Given the context of mandatory disclosure to the regulator about a commercial milestone, RNS is the best fit.
2023-07-19 Spanish
La Sociedad anuncia que su socio, Lotus Pharmaceutical CO., Ltd. ha recibido la aprobación acelerada para la comercialización de Zepzelca® (lurbinectedina) en Taiwan.
Regulatory Filings Classification · 100% confidence The document is a formal communication dated July 11, 2023, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - Spanish Securities Market Commission). It is titled 'OTRA INFORMACIÓN RELEVANTE' (OTHER RELEVANT INFORMATION) and announces that PharmaMar's partner received accelerated approval in Taiwan for the drug Zepzelca®. The text explicitly states, 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia' (A press release that will be distributed to the media regarding this news is attached). This structure—a brief regulatory notification forwarding an attached press release about a significant business event (drug approval)—is characteristic of a general regulatory announcement that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal regulatory disclosure that doesn't fit a more specific category like DIV, DIRS, or MANG, the most appropriate fallback is Regulatory Filings (RNS). The document length is moderate (6899 chars), but its function is clearly to disseminate 'Other Relevant Information' as required by market regulations.
2023-07-11 Spanish
La Sociedad remite detalle de las operaciones del Contrato de Liquidez comprendidas entre el 01/04/2023 y el 30/06/2023
Transaction in Own Shares Classification · 98% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. The title is 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and the subject is 'Operaciones trimestrales contrato de liquidez' (Quarterly operations under the liquidity contract). It details the purchases and sales of own shares conducted under a liquidity agreement during the second quarter of 2023 (April 1 to June 30, 2023). This type of mandatory disclosure regarding transactions in a company's own shares (share repurchase/issuance) falls directly under the definition of 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS) because it is highly specific, nor is it a report announcement (RPA) as it contains the detailed data itself.
2023-07-05 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.